Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patientsFÄTKENHEUER, Gerd; STASZEWSKI, Schlomo; PLETTENBURG, Andreas et al.AIDS (London). 2009, Vol 23, Num 16, pp 2117-2124, issn 0269-9370, 8 p.Article

Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoirWESTBY, Mike; LEWIS, Marilyn; WHITCOMB, Jeannette et al.Journal of virology. 2006, Vol 80, Num 10, pp 4909-4920, issn 0022-538X, 12 p.Article